Cellectar Biosciences Inc (CLRB)
3.06
+0.04
(+1.32%)
USD |
NASDAQ |
Apr 26, 15:20
Cellectar Biosciences Free Cash Flow (Quarterly): -9.862M for Dec. 31, 2023
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -9.862M |
| September 30, 2023 | -8.665M |
| June 30, 2023 | -7.530M |
| March 31, 2023 | -7.184M |
| December 31, 2022 | -7.530M |
| September 30, 2022 | -7.020M |
| June 30, 2022 | -5.829M |
| March 31, 2022 | -5.070M |
| December 31, 2021 | -4.641M |
| September 30, 2021 | -6.433M |
| June 30, 2021 | -6.884M |
| March 31, 2021 | -4.753M |
| December 31, 2020 | -3.886M |
| September 30, 2020 | -3.502M |
| June 30, 2020 | -3.084M |
| March 31, 2020 | -3.523M |
| December 31, 2019 | -2.687M |
| September 30, 2019 | -3.548M |
| June 30, 2019 | -2.662M |
| March 31, 2019 | -2.822M |
| December 31, 2018 | -3.127M |
| September 30, 2018 | -2.969M |
| June 30, 2018 | -2.546M |
| March 31, 2018 | -3.186M |
| December 31, 2017 | -2.826M |
| Date | Value |
|---|---|
| September 30, 2017 | -2.569M |
| June 30, 2017 | -2.918M |
| March 31, 2017 | -3.054M |
| December 31, 2016 | -2.416M |
| September 30, 2016 | -2.215M |
| June 30, 2016 | -1.906M |
| March 31, 2016 | -1.818M |
| December 31, 2015 | -1.513M |
| September 30, 2015 | -2.171M |
| June 30, 2015 | -2.196M |
| March 31, 2015 | -2.392M |
| December 31, 2014 | -2.153M |
| September 30, 2014 | -2.099M |
| June 30, 2014 | -2.008M |
| March 31, 2014 | -2.610M |
| December 31, 2013 | -2.692M |
| September 30, 2013 | -2.595M |
| June 30, 2013 | -2.034M |
| March 31, 2013 | -1.982M |
| December 31, 2012 | -1.754M |
| September 30, 2012 | -1.699M |
| June 30, 2012 | -1.512M |
| March 31, 2012 | -1.718M |
| December 31, 2011 | -1.542M |
| September 30, 2011 | -1.620M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-9.862M
Minimum
Dec 2023
-2.662M
Maximum
Jun 2019
-5.489M
Average
-5.070M
Median
Mar 2022
Free Cash Flow (Quarterly) Benchmarks
| Perspective Therapeutics Inc | -9.097M |
| Eli Lilly and Co | -1.963B |
| Actinium Pharmaceuticals Inc | -7.49M |
| Bristol-Myers Squibb Co | 3.922B |
| Altimmune Inc | -16.53M |